FIA
ATHE

FNY Investment Advisers’s Alterity Therapeutics ATHE Stock Holding History

FNY Investment Advisers’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-385
Closed -$4K – 483
2020
Q2 		$4K Buy
+385
New +$2.45K ﹤0.01% 331

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

FNY Investment Advisers's ATHE Position: Q3 2020 in Review

FNY Investment Advisers sold out of Alterity Therapeutics (ATHE) in Q3 2020, closing a stake of 385 shares — an estimated $4K sold.

FNY Investment Advisers first reported a position in ATHE in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 10 funds tracked by Wall St. Rank hold ATHE as of Q3 2020.

  • FNY Investment Advisers reported no remaining Alterity Therapeutics position as of Q3 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 385 Alterity Therapeutics shares in Q3 2020, an estimated $4K.
  • FNY Investment Advisers first reported a position in Alterity Therapeutics in Q2 2020 and held it in 1 quarter.
  • FNY Investment Advisers's Alterity Therapeutics position peaked at $4K in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2020.

Based on FNY Investment Advisers's 13F filing for Q3 2020, filed 9 Oct 2020.